The Janus Kinase (JAK) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Janus Kinase (JAK) Inhibitors Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Janus Kinase (JAK) Inhibitors Market.

Some of the key takeaways from the Janus Kinase (JAK) Inhibitors Pipeline Report:

• Companies across the globe are diligently working toward developing novel Janus Kinase (JAK) Inhibitors treatment therapies with a considerable amount of success over the years. 

• Janus Kinase (JAK) Inhibitors companies working in the treatment market are Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others, are developing therapies for the Janus Kinase (JAK) Inhibitors treatment 

• Emerging Janus Kinase (JAK) Inhibitors therapies in the different phases of clinical trials are- Research programme: JAK2 inhibitors Ajax Therapeutics, SDC 1802, INCB-160058, ATI-2138, AZD 4604, CPL409116, Zasocitinib, Povorcitinib, Upadacitinib, Baricitinib, and others are expected to have a significant impact on the Janus Kinase (JAK) Inhibitors market in the coming years.   

• In March 2024, Incyte released findings from a Phase II trial assessing the effectiveness and safety of povorcitinib (INCB54707), an oral JAK1 inhibitor, in adults with prurigo nodularis (PN). These results were presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting held from March 8-12, 2024, in San Diego.

• In October 2023, Aclaris Therapeutics declared the conclusion of patient enrollment in ATI-1777-AD-202, its Phase IIb study investigating the topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in individuals with mild to severe atopic dermatitis.

• In February 2023, Incyte Corporation has initiated a Phase III trial, which is double-blind, randomized, and placebo-controlled, to assess the efficacy and safety of povorcitinib (INCB054707) in individuals with moderate to severe hidradenitis suppurativa. The study aims to evaluate povorcitinib’s effectiveness and safety over a 12-week period compared to placebo, followed by a 42-week extension phase. The trial is currently enrolling participants, with an estimated enrollment of 600 individuals, and is projected to conclude by March 2025.

• In October 2022, AbbVie announced that the FDA has approved upadacitinib, marketed as Rinvoq, a Janus kinase (JAK) inhibitor. The approval is specifically for adults diagnosed with non-radiographic axial spondyloarthritis (nr-axSpA) who have objective signs of inflammation and have had an insufficient response to or cannot tolerate one or more tumor necrosis factor (TNF) inhibitors.

Janus Kinase (JAK) Inhibitors Overview

Janus kinase (JAK) inhibitors are a class of medications that target the Janus kinase enzymes, specifically JAK1, JAK2, JAK3, and TYK2. These enzymes are involved in signaling pathways that regulate the immune system and inflammatory processes. By inhibiting JAK enzymes, JAK inhibitors can modulate immune responses and reduce inflammation.

Get a Free Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitor-pipeline-insight

Emerging Janus Kinase (JAK) Inhibitors Drugs Under Different Phases of Clinical Development Include:

• Research programme: JAK2 inhibitors Ajax Therapeutics

• SDC 1802: Sareum

• INCB-160058: Incyte Corporation

• ATI-2138: Aclaris Therapeutics

• AZD 4604: AstraZeneca

• CPL409116: Celon Pharma

• Zasocitinib: Takeda

• Povorcitinib: Incyte Corporation

• Upadacitinib: AbbVie

• Baricitinib: Eli Lilly and Company

Janus Kinase (JAK) Inhibitors Route of Administration

Janus Kinase (JAK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Janus Kinase (JAK) Inhibitors Molecule Type

Janus Kinase (JAK) Inhibitors Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Janus Kinase (JAK) Inhibitors Pipeline Therapeutics Assessment

• Janus Kinase (JAK) Inhibitors Assessment by Product Type

• Janus Kinase (JAK) Inhibitors By Stage and Product Type

• Janus Kinase (JAK) Inhibitors Assessment by Route of Administration

• Janus Kinase (JAK) Inhibitors By Stage and Route of Administration

• Janus Kinase (JAK) Inhibitors Assessment by Molecule Type

• Janus Kinase (JAK) Inhibitors by Stage and Molecule Type

DelveInsight’s Janus Kinase (JAK) Inhibitors Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Janus Kinase (JAK) Inhibitors product details are provided in the report. Download the Janus Kinase (JAK) Inhibitors pipeline report to learn more about the emerging Janus Kinase (JAK) Inhibitors therapies

Some of the key companies in the Janus Kinase (JAK) Inhibitors Therapeutics Market include:

Key companies developing therapies for Janus Kinase (JAK) Inhibitors are – Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, and others.

Janus Kinase (JAK) Inhibitors Pipeline Analysis:

The Janus Kinase (JAK) Inhibitors pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Janus Kinase (JAK) Inhibitors with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Janus Kinase (JAK) Inhibitors Treatment.

• Janus Kinase (JAK) Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Janus Kinase (JAK) Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Janus Kinase (JAK) Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors drugs and therapies

Janus Kinase (JAK) Inhibitors Pipeline Market Drivers

• JAK inhibitors offer therapeutic benefits by modulating the immune system and reducing inflammation in conditions like rheumatoid arthritis and psoriasis. This trend is fueling the growth of the JAK inhibitor market, addressing unmet medical needs in rheumatology and dermatology.

Janus Kinase (JAK) Inhibitors Pipeline Market Barriers

• Janus kinase (JAK) Inhibitors pricing is still highly uncontrolled and determined on a case-by-case basis in many nations, frequently focusing on a single upfront payment. 

Scope of Janus Kinase (JAK) Inhibitors Pipeline Drug Insight    

• Coverage: Global

• Key Janus Kinase (JAK) Inhibitors Companies: Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others

• Key Janus Kinase (JAK) Inhibitors Therapies: Research programme: JAK2 inhibitors Ajax Therapeutics, SDC 1802, INCB-160058, ATI-2138, AZD 4604, CPL409116, Zasocitinib, Povorcitinib, Upadacitinib, Baricitinib, and others

• Janus Kinase (JAK) Inhibitors Therapeutic Assessment: Janus Kinase (JAK) Inhibitors current marketed and Janus Kinase (JAK) Inhibitors emerging therapies

• Janus Kinase (JAK) Inhibitors Market Dynamics: Janus Kinase (JAK) Inhibitors market drivers and Janus Kinase (JAK) Inhibitors market barriers 

Request for Sample PDF Report for Janus Kinase (JAK) Inhibitors Pipeline Assessment and clinical trials

Table of Contents

1. Janus Kinase (JAK) Inhibitors Report Introduction

2. Janus Kinase (JAK) Inhibitors Executive Summary

3. Janus Kinase (JAK) Inhibitors Overview

4. Janus Kinase (JAK) Inhibitors- Analytical Perspective In-depth Commercial Assessment

5. Janus Kinase (JAK) Inhibitors Pipeline Therapeutics

6. Janus Kinase (JAK) Inhibitors Late Stage Products (Phase II/III)

7. Janus Kinase (JAK) Inhibitors Mid Stage Products (Phase II)

8. Janus Kinase (JAK) Inhibitors Early Stage Products (Phase I)

9. Janus Kinase (JAK) Inhibitors Preclinical Stage Products

10. Janus Kinase (JAK) Inhibitors Therapeutics Assessment

11. Janus Kinase (JAK) Inhibitors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Janus Kinase (JAK) Inhibitors Key Companies

14. Janus Kinase (JAK) Inhibitors Key Products

15. Janus Kinase (JAK) Inhibitors Unmet Needs

16 . Janus Kinase (JAK) Inhibitors Market Drivers and Barriers

17. Janus Kinase (JAK) Inhibitors Future Perspectives and Conclusion

18. Janus Kinase (JAK) Inhibitors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/